Phase 2 clinical trials have demonstrated that GLP-3 can reduce body weight by up to 24.2% over a 48-week period, while also improving cardiometabolic parameters such as blood pressure, lipid profile, and insulin sensitivity
Although present observations have unveiled the practical meaning of promoted FAO via LCA in obesity-dependent AF, and indicating the leading role of FAO in AF pathogenesis, this study failed to directly assess the efficiency of FAs uptake or FAO in vivo , and whether the LCA-conferred anti-AF effects is mediated by AMPK also needs confirmation in vivo
If pregnant, planning pregnancy, or breastfeeding, to review safety and treatment alternatives
Some studies have speculated that it may be related to genetic factors, ionizing radiation, or malignant transformation of a neurofibromas, but there is no clear evidence [2,3,4]